knowledge -WSS

knowledge

author：knowledge 2025-09-27 12:35:36 - browse：39

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Why do women spend more than men on medical expenses?

WSS

Texas Medical Board asked to define abortion emergency exception

A single Democrat is willing to weaken Medicare negotiation power

Covid vaccines: Private market messier than government rollout

Why CTE doesn’t keep Americans from enjoying the Super Bowl

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Updated Covid vaccine has 54% effectiveness, new study suggests

focus

knowledge

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Listen: Who gets the credit for GLP

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

After a drawn out lobbying fight, ARPA

Medical records are filled with copy

Bernie brings in new pharma CEOs to talk drug prices

Supreme Court strikes down use of affirmative action

Texas Medical Board asked to define abortion emergency exception

At least 13 dead in Texas as scorching temps continue

A single Democrat is willing to weaken Medicare negotiation power

entertainment

Padmanee Sharma of MD Anderson at center of lawsuit over credit

A protest over insulin prices is seen as a fight for life

Problems with a popular proposal to regulate AI in health care

Padmanee Sharma of MD Anderson at center of lawsuit over credit

WHO recommends dropping component of many flu vaccines

Why Novartis is going to walk from its acquisition of MorphoSys

hotspot

hotspot

focus

leisure time